Related Experiment Videos
New drugs in breast cancer
1Breast Unit Research Group, Western General Hospital, Edinburgh, UK.
Abstract:
The 1990s have seen the emergence of several classes of new efficacious drugs which have become established as treatment for breast cancer. Thus, aromatase inhibitors, taxanes and herceptin have all emerged as potentially valuable therapeutic agents for treatment of advanced breast cancer. Bisphosphonates have found a place in preventing skeletal complications in breast cancer patients with bone metastasis. Tamoxifen has a new role in chemoprevention in patients at high risk of breast cancer. This paper summarises these results.
Insights
New breast cancer drugs like aromatase inhibitors, taxanes, and Herceptin offer valuable treatments for advanced disease. Bisphosphonates prevent bone issues, and Tamoxifen aids high-risk prevention.
Area of Science:
- Oncology
- Pharmacology
Background:
- The 1990s marked significant advancements in breast cancer therapeutics.
- Several novel drug classes emerged, transforming treatment paradigms.
Purpose of the Study:
- To summarize key therapeutic advancements in breast cancer treatment from the 1990s.
- To highlight the established roles of new drug classes and their specific applications.
Main Methods:
- Review of emerging drug classes and their clinical applications in breast cancer.
- Synthesis of data on the efficacy and established uses of new agents.
Main Results:
- Aromatase inhibitors, taxanes, and Herceptin are established treatments for advanced breast cancer.
- Bisphosphonates are utilized for preventing skeletal complications in metastatic breast cancer.
- Tamoxifen has demonstrated efficacy in breast cancer chemoprevention for high-risk individuals.
Conclusions:
- The 1990s introduced highly effective drugs that have become cornerstones of breast cancer therapy.
- These advancements offer improved outcomes for patients with advanced disease and skeletal metastases, as well as preventative strategies.